Cezanne to Use Lumiphore Reagents in Dx Tests | GenomeWeb

NEW YORK (GenomeWeb News) – Brahms subsidiary Cezanne will incorporate technology from Lumiphore in its diagnostic tests under two new agreements, Richmond, Calif.-based Lumiphore said today.

Brahms and Cezanne will use the Lumi4-Tb technology in development of current and future diagnostic tests under a non-exclusive agreement. In addition, Cezanne acquired exclusive rights to use the technology in diagnostic tests for Down's Syndrome, including tests for Trisomy 21, 13 and 18, Triploidy, Translocation, and Mosaicism, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.